Although we have seen major drop-in death rates & improved 5 years survival for patients with cancer, 5-year survival rates for cancer patients are lower in Lower- and Middle-Income Countries (LMICs) compared to USA & Europe. Newer drugs like Immunotherapy & Targeted therapies are effective from the clinical standpoint but do not turn out to be cost effective every time. Access to companion diagnostics is also similar challenge. LMICs also spend less on cancer control and care. An initiative like UN declaration on NCDs is aiming to achieve at access to 80% essential cancer medicines by 2025. Quality generics & Biosimilars, Price discrimination like Tiered Pricing can improve the access to cancer drugs. Universal coverage would be the most important alternative to improve the access to cancer medications.